Meeting of the National Vaccine Advisory Committee, 3094-3095 [06-493]
Download as PDF
<![CDATA[
3094
Federal Register / Vol. 71, No. 12 / Thursday, January 19, 2006 / Notices
Individual), Benjamin Graebel, Vice
Chairman.
Oriental Logistics Miami, Inc., 7200 NW
19th Street, Suite 302, Miami, FL
33126. Officers: Anly Liu, Vice
President (Qualifying Individual),
Samuel Wong, President.
St. John Freight Systems, Inc., #404, 190
Middlesex Essex Turnpike, Iselin, NJ
08830. Officers: Kenneth Carr,
Secretary (Qualifying Individual),
Chandramouleesware Jagadeeswari,
President.
TMO Global Logistics, LLC, 600 Peter
Jefferson Parkway, Suite 310,
Charlottesville, VA 22911. Officer:
Mia Josephine Aguilar, Manager
(Qualifying Individual).
Global International Shipping Inc. dba
G.I.S., 125 S. Elm Street, Suite 202,
Greensboro, NC 27401. Officers: Ziad
H. Najjar, President, Huthaifa Aladwan, Partner (Qualifying
Individuals).
Shipex LLC, 3341 Rauch Street,
Houston, TX 77029. Officers:
Mohamed F. El-Khodiry, C.O.O.
(Qualifying Individual), Sari Ghazal,
Member.
KPAC Aerocean, Inc. dba Aerocean
Transport Services, 550 E. Carson
Plaza Drive, Suite 109, Carson, CA
90746. Officer: Young Ho Kang,
President (Qualifying Individual).
Ocean Freight Forwarder—Ocean
Transportation Intermediary
Applicants
West Coast Forwarding, Inc., 1028 North
Lake Avenue, Suite 202, Pasadena,
CA 91104. Officers: David O’Donnell,
President (Qualifying Individual),
Aimee Saye, Vice President.
RG Logistics Ltd., 111 Madison Avenue,
Hempstead, NY 11550. Officer: Roy
Ghirdarry, President (Qualifying
Individual).
Board of Governors of the Federal Reserve
System, January 13, 2006.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E6–571 Filed 1–18–06; 8:45 am]
Dated: January 13, 2006.
Bryant L. VanBrakle,
Secretary.
[FR Doc. E6–566 Filed 1–18–06; 8:45 am]
BILLING CODE 6730–01–P
BILLING CODE 6210–01–S
FEDERAL RESERVE SYSTEM
sroberts on PROD1PC70 with NOTICES
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
VerDate Aug<31>2005
16:38 Jan 18, 2006
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The application also will be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Additional information on all bank
holding companies may be obtained
from the National Information Center
Web site at https://www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than February 13,
2006.
A. Federal Reserve Bank of
Richmond (A. Linwood Gill, III, Vice
President) 701 East Byrd Street,
Richmond, Virginia 23261-4528:
1. BB&T Corporation, Winston Salem,
North Carolina; to acquire 100 percent
of the voting shares of Main Street
Banks, Inc., Atlanta, Georgia, and
thereby indirectly acquire Main Street
Bank, Covington, Georgia. In connection
with this application, applicant also
proposes to engage in data processing
activities, pursuant to Section
225.28(b)(14) of Regulation Y.
Jkt 208001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the National Vaccine
Advisory Committee
Office of the Secretary,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
SUMMARY: As stipulated by the Federal
Advisory Committee Act, the
Department of Health and Human
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Services (DHHS) is hereby giving notice
that the National Vaccine Advisory
Committee (NVAC) will hold a meeting.
The meeting is open to the public.
DATES: The meeting will be held on
February 7, 2006, from 9 a.m. to 5 p.m.,
and on February 8, 2006, from 9 a.m. to
1 p.m.
ADDRESSES: Department of Health and
Human Services; Hubert H. Humphrey
Building, Room 800; 200 Independence
Avenue, SW., Washington, DC 20201.
FOR FURTHER INFORMATION CONTACT: Ms.
Emma English, Program Analyst,
National Vaccine Program Office,
Department of Health and Human
Services, Room 443–H Hubert H.
Humphrey Building, 200 Independence
Avenue, SW., Washington, DC 20201;
(202) 690–5566, nvac@osophs.dhhs.gov.
SUPPLEMENTARY INFORMATION: Pursuant
to Section 2101 of the Public Service
Act (42 U.S.C. 300aa–1), the Secretary of
Health and Human Services was
mandated to establish the National
Vaccine Program to achieve optimal
prevention of human infectious diseases
through immunization and to achieve
optimal prevention against adverse
reactions to vaccines. The National
Vaccine Advisory Committee was
established to provide advice and make
recommendations to the Assistant
Secretary for Health, as the Director of
the National Vaccine Program, on
matters related to the program’s
responsibilities.
Topics to be discussed at the meeting
include the 2006–2007 influenza
season, state pandemic influenza
preparedness, poliomyelitis outbreaks
in Minnesota, and the insurance
coverage for vaccines. Updates will be
given by various subcommittees and
working groups. A tentative agenda will
be made available on or about January
23, 2006 for review on the NVAC Web
site: https://www.hhs.gov/nvpo/nvac.
Public attendance at the meeting is
limited to space available. Individuals
must provide a photo ID for entry into
the Humphrey Building. Individuals
who plan to attend and need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should notify the
designated contact person. Members of
the public will have the opportunity to
provide comments at the meeting.
Public comment will be limited to five
minutes per speaker. Any members of
the public who wish to have printed
material distributed to NVAC members
should submit materials to the
Executive Secretary, NVAC, through the
contact person listed above prior to
close of business January 31, 2006.
Preregistration is required for both
E:\FR\FM\19JAN1.SGM
19JAN1
Federal Register / Vol. 71, No. 12 / Thursday, January 19, 2006 / Notices
public attendance and comment. Any
individual who wishes to attend the
meeting and/or participate in the public
comment session should e-mail
nvac@osophs.dhhs.gov or call 202–690–
5566.
Dated: January 11, 2006.
Bruce Gellin,
Director, National Vaccine Program Office.
[FR Doc. 06–493 Filed 1–18–06; 8:45 am]
BILLING CODE 4150–44–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
National Institute for Occupational
Safety and Health; Proposed Changes
to the Dose Reconstruction Target
Organ Selection for Lymphoma Under
the Energy Employees Occupational
Illness Compensation Program Act of
2000
Authority: 42 CFR 82.32, 67 FR 22335–
22336.
Department of Health and
Human Services (HHS), Centers for
Disease Control and Prevention (CDC).
AGENCY:
sroberts on PROD1PC70 with NOTICES
ACTION:
Notice for public comment.
SUMMARY: The National Institute for
Occupational Safety and Health
(NIOSH) proposes to change the
selection of target organs used in dose
reconstructions NIOSH produces under
the Energy Employees Occupational
Illness Compensation Program Act of
2000 (EEOICPA) for energy employees
with lymphoma cancers. This proposed
change is in response to an evaluation
by NIOSH of current scientific data on
lymphoma, which revealed that the site
of the radiation injury can differ from
the site of the tumor or cancer origin
documented in the medical files of a
lymphoma cancer patient. The new
process for selecting dose reconstruction
target organs for energy employees with
lymphoma cancers would include
selecting the target organ that would
have received the highest radiation dose
from among relevant, possibly irradiated
organs, as determined through the dose
reconstruction process, when the
identity of the target organ is in
question. This change would result in
the Department of Labor calculating
higher probability of causation
determinations for select lymphoma
cases among previously decided and
current EEOICPA cancer claims.
NIOSH must receive public
comments on this proposed change on
DATES:
VerDate Aug<31>2005
16:38 Jan 18, 2006
Jkt 208001
or before 15 days after the date of
publication in the Federal Register.
ADDRESSES: Mail comments concerning
this proposed change to Larry Elliott,
Director, Office of Compensation
Analysis and Support, National Institute
for Occupational Safety and Health,
4676 Columbia Parkway, Mailstop C–46,
Cincinnati, Ohio 45226. Submit
electronic comments to
OCAS@CDC.GOV.
FOR FURTHER INFORMATION CONTACT:
Larry Elliott, Director, Office of
Compensation Analysis and Support,
National Institute for Occupational
Safety and Health, 4676 Columbia
Parkway, Mailstop C–46, Cincinnati, OH
45226, Telephone: (513) 533–6800 (This
is not a toll-free number).
SUPPLEMENTARY INFORMATION: NIOSH
conducts radiation dose reconstructions
under EEOICPA in compliance with the
dose reconstruction methods specified
in HHS regulations at 42 CFR part 82.
These regulations provide for NIOSH to
update its dose reconstruction methods
as necessary on the basis of improved
scientific understanding and specify a
process for deciding and implementing
such updates (41 CFR 82.30–82.33).
Accordingly, NIOSH is currently
proposing to update its method for
reconstructing radiation doses in cases
involving certain lymphoma cancers.
Specifically, NIOSH is proposing to
change its method for identifying the
target organ for which radiation doses
will be reconstructed in these cases, for
the reasons described below. As
required for certain updates in dose
reconstruction methods, NIOSH will
present the proposed change to the
Advisory Board on Radiation and
Worker Health for its comments. NIOSH
will also consider all public comments
concerning this change that are received
prior to the comment deadline, as
specified above.
NIOSH has re-examined the
appropriateness of the current method
of selecting dosimetry target organs for
lymphoma cases in light of the current
scientific knowledge on the diagnosis
and etiology of the various forms of
lymphoma.1 This re-examination has
revealed that for many non-Hodgkin’s
1 Crowther, M. Consultant’s Report, Dose
Reconstruction Project. Prepared for the National
Institute for Occupational Safety and Health Office
of Compensation Analysis and Support. 2005;
Eckerman, K.F. Target Organs for Lymphatic and
Hematopoietic Cancers Comments/Suggestions.
Prepared for the National Institute for Occupational
Safety and Health Office of Compensation Analysis
and Support. 2005. Available online at: https://
www.cdc.gov/niosh/ocas/ocasdose.html. (This
information can be found on the aforementioned
Web page under the ‘‘Miscellaneous Items’’ heading
in the section ‘‘Evaluation of Target Organ for
Lymphomas.’’)
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
3095
lymphomas, there are two problems
with NIOSH’s current target organ
selection method. First, the site of
occurrence of the tumor is not
necessarily the site of the original
radiation injury. Second, the site listed
in the diagnosis may not actually be the
site of primary involvement. Rather, it is
common to list the site of the biopsy,
which may be selected on the basis of
medical considerations in terms of the
clinical symptoms and condition of the
patient and the ease of surgical access.
Both of these problems contribute to the
possibility that under current methods
for select lymphoma cases, NIOSH is
not certain to be basing its dose
reconstruction on the organ that has the
highest radiation dose and may have
been the site of origin of the lymphoma
of the energy employee.
As a result of this re-evaluation,
NIOSH proposes to modify the selection
of target organs in select lymphoma
cases so that the organ that would have
received the highest radiation dose from
among relevant, possibly irradiated
organs, as determined through the dose
reconstruction process, is used in the
dose reconstruction. For the subset of
lymphomas where tumor location is
informative about the probable site of
the original radiation injury (e.g.
Hodgkin’s disease, lymphosarcoma,
etc.), information related to the site of
diagnosis would be considered in target
organ selection.
This proposed change pertains only to
the selection of the appropriate target
organ as the site of radiation injury (i.e.,
for calculation of effective radiation
dose during the dose reconstruction
process). It has no bearing on the
selection of the appropriate Interactive
Radiological Epidemiology Program
(IREP) cancer risk model for
determining probability of causation,
nor does it impact the cancer risk
models themselves.
This proposed change in NIOSH dose
reconstruction methods would be likely
to have a substantial effect on certain
EEOICPA cancer cases involving
lymphomas. NIOSH would review all
relevant completed dose reconstructions
for cases that have not been
compensated to identify those for which
this new method is applicable, and
would re-complete these dose
reconstructions using this new method,
and would apply this new method to all
current and future cases undergoing
dose reconstruction. Application of this
new method would result in the
Department of Labor calculating higher
probability of causation determinations
for select lymphoma cases among
previously decided and current
EEOICPA cancer claims.
E:\FR\FM\19JAN1.SGM
19JAN1
]]>Agencies
[Federal Register Volume 71, Number 12 (Thursday, January 19, 2006)]
[Notices]
[Pages 3094-3095]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-493]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the National Vaccine Advisory Committee
AGENCY: Office of the Secretary, Department of Health and Human
Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, the
Department of Health and Human Services (DHHS) is hereby giving notice
that the National Vaccine Advisory Committee (NVAC) will hold a
meeting. The meeting is open to the public.
DATES: The meeting will be held on February 7, 2006, from 9 a.m. to 5
p.m., and on February 8, 2006, from 9 a.m. to 1 p.m.
ADDRESSES: Department of Health and Human Services; Hubert H. Humphrey
Building, Room 800; 200 Independence Avenue, SW., Washington, DC 20201.
FOR FURTHER INFORMATION CONTACT: Ms. Emma English, Program Analyst,
National Vaccine Program Office, Department of Health and Human
Services, Room 443-H Hubert H. Humphrey Building, 200 Independence
Avenue, SW., Washington, DC 20201; (202) 690-5566,
nvac@osophs.dhhs.gov.
SUPPLEMENTARY INFORMATION: Pursuant to Section 2101 of the Public
Service Act (42 U.S.C. 300aa-1), the Secretary of Health and Human
Services was mandated to establish the National Vaccine Program to
achieve optimal prevention of human infectious diseases through
immunization and to achieve optimal prevention against adverse
reactions to vaccines. The National Vaccine Advisory Committee was
established to provide advice and make recommendations to the Assistant
Secretary for Health, as the Director of the National Vaccine Program,
on matters related to the program's responsibilities.
Topics to be discussed at the meeting include the 2006-2007
influenza season, state pandemic influenza preparedness, poliomyelitis
outbreaks in Minnesota, and the insurance coverage for vaccines.
Updates will be given by various subcommittees and working groups. A
tentative agenda will be made available on or about January 23, 2006
for review on the NVAC Web site: https://www.hhs.gov/nvpo/nvac.
Public attendance at the meeting is limited to space available.
Individuals must provide a photo ID for entry into the Humphrey
Building. Individuals who plan to attend and need special assistance,
such as sign language interpretation or other reasonable
accommodations, should notify the designated contact person. Members of
the public will have the opportunity to provide comments at the
meeting. Public comment will be limited to five minutes per speaker.
Any members of the public who wish to have printed material distributed
to NVAC members should submit materials to the Executive Secretary,
NVAC, through the contact person listed above prior to close of
business January 31, 2006. Preregistration is required for both
[[Page 3095]]
public attendance and comment. Any individual who wishes to attend the
meeting and/or participate in the public comment session should e-mail
nvac@osophs.dhhs.gov or call 202-690-5566.
Dated: January 11, 2006.
Bruce Gellin,
Director, National Vaccine Program Office.
[FR Doc. 06-493 Filed 1-18-06; 8:45 am]
BILLING CODE 4150-44-P
